GlassScriptPhysician profile
David MD Vesco
NPI 1629084074
$8,141.30
in general payments reported to CMS, 2019-2025
26 companies · $1,106 in 2025
The $1,106 reported for 2025 was more than what 86% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,263 · 2020: $991 · 2021: $1,745 · 2022: $852 · 2023: $1,079 · 2024: $1,107 · 2025: $1,106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,290.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $4,248.50 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $1,074.08 | 2019-2025 | Breztri, Airsupra |
| Lilly USA, LLC | $625.43 | 2019-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $360.16 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $310.83 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $282.21 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $199.62 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $148.93 | 2022 | |
| Arbor Pharmaceuticals, INC. | $115.02 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $98.47 | 2022-2023 | Xarelto |
| Glaxosmithkline, LLC. | $80.07 | 2022-2023 | Trelegy Ellipta, Shingrix |
| Abbott Laboratories | $68.61 | 2022-2023 | Freestyle Libre 2 |
| Novartis Pharmaceuticals Corporation | $66.00 | 2023-2025 | |
| Abbvie INC. | $62.79 | 2021-2024 | |
| Bausch Health US, LLC | $58.85 | 2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $56.03 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $55.08 | 2021 | |
| Sumitomo Pharma America, INC. | $48.74 | 2023 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $43.16 | 2022 | |
| Urovant Sciences INC | $24.84 | 2022 | |
| Amarin Pharma, INC. | $24.65 | 2021 | |
| Lupin INC. | $22.08 | 2019 | |
| Lundbeck LLC | $18.89 | 2021 | |
| Azurity Pharmaceuticals, INC. | $18.05 | 2024 | Edarbi |
| Kowa Pharmaceuticals America, INC. | $16.83 | 2021 | |
| Gilead Sciences, INC. | $13.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Vesco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.